![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 12 of 12. This is the beginning of the thread.
Posted by linkadge on May 13, 2005, at 21:15:30
This agent looks promising.
http://www.dovpharm.com/sub_page/product_dov216303.html
Linkadge
Posted by linkadge on May 13, 2005, at 21:25:17
In reply to DOV 216 303, posted by linkadge on May 13, 2005, at 21:15:30
Posted by The Resistance on May 14, 2005, at 8:15:43
In reply to DOV 216 303, posted by linkadge on May 13, 2005, at 21:15:30
I've been interested in this for a while, but the information on the link is quite old.
I wonder what the currant story on it is?
Hope its still in development.
Posted by linkadge on May 14, 2005, at 14:59:42
In reply to Re: DOV 216 303, posted by The Resistance on May 14, 2005, at 8:15:43
Perhaps I might have a responce similar to the one I had for SJW which also is a triple uptake inhibitor.
Linkadge
Posted by Dave001 on May 14, 2005, at 16:41:50
In reply to Re: DOV 216 303, posted by The Resistance on May 14, 2005, at 8:15:43
> I've been interested in this for a while, but the information on the link is quite old.
>
> I wonder what the currant story on it is?Dunno. There was an article about it in the Journal of Clinical Pharmacology back in December.
Beer, B., J. Stark, et al. (2004). "DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile." J Clin Pharmacol 44(12): 1360-7.
Link to abstract:
http://jcp.sagepub.com/cgi/content/abstract/44/12/1360I just downloaded the full article and will read it later to see if they mention anything about its development status. A better place to find that out would probably be the FDA's web site or related resource.
> Hope its still in development.
Posted by linkadge on May 14, 2005, at 17:21:36
In reply to Re: DOV 216 303, posted by Dave001 on May 14, 2005, at 16:41:50
Soemthing like this would really be a change. Or perhaps an indicator.
To see what kind of difference that a relativly equal uptake inhibitor can have on depression is compelling.
It is funny cause drugs like ritalin are really tripple uptake inhibitors. I found ritalin superior to all for depression.
Linkadge
Posted by mike13 on May 14, 2005, at 20:08:49
In reply to Re: DOV 216 303, posted by linkadge on May 14, 2005, at 17:21:36
Posted by alienatari on May 15, 2005, at 8:34:33
In reply to DOV 216 303, posted by linkadge on May 13, 2005, at 21:15:30
http://www.biopsychiatry.com/antidepressantbroad.htm
"Broad spectrum" antidepressants: Is more better
for the treatment of depression?
by
Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS.
DOV Pharmaceutical, Inc.,
433 Hackensack Avenue,
07601, Hackensack, NJ, USA
Life Sci. 2003 Nov 7;73(25):3175-9ABSTRACT
The majority of antidepressants in current use selectively inhibit the reuptake of serotonin and/or norepinephrine. "Broad spectrum" antidepressants are compounds that inhibit the reuptake of norepinephrine, serotonin and dopamine, the three biogenic amines most closely linked to depression. The pharmacological profile of one such compound has recently been described (European Journal of Pharmacology, 461 (2003) 99). DOV 21,947, an azabicyclo[3.1.0]hexane, potently inhibits norepinephrine, serotonin and dopamine reuptake by the corresponding human transporter proteins. DOV 21,947 is orally active in the forced swim and tail suspension tests, preclinical procedures that are highly predictive of antidepressant action in patients. A closely related compound, DOV 216,303 is safe and well-tolerated in Phase I studies. The plasma concentrations of DOV 216,303 following both single and multiple doses appear sufficient to inhibit norepinephrine, serotonin, and dopamine reuptake. Based on the pivotal role proposed for dopamine in depression, it has been hypothesized that a broad spectrum antidepressant will produce a more rapid onset and/or higher efficacy than agents inhibiting the reuptake of serotonin and/or norepinephrine.
Posted by KaraS on May 15, 2005, at 18:18:41
In reply to DOV 216 303, posted by linkadge on May 13, 2005, at 21:15:30
This is many, many years away from market, isn't it?
k
Posted by linkadge on May 15, 2005, at 19:52:37
In reply to Re: DOV 216 303, posted by KaraS on May 15, 2005, at 18:18:41
We need MAOI like effacacy in a safer pill.
Linkadge
Posted by KaraS on May 15, 2005, at 22:50:58
In reply to Re: DOV 216 303, posted by linkadge on May 15, 2005, at 19:52:37
> We need MAOI like effacacy in a safer pill.
>
> Linkadge
Absolutely! But how long will we have to wait for this one?k
Posted by Dave001 on June 11, 2005, at 14:42:36
In reply to Re: DOV 216 303, posted by KaraS on May 15, 2005, at 18:18:41
> This is many, many years away from market, isn't it?
Well, it supposedly underwent phase I trials a couple of years ago or so. But unfortunately, safety and efficacy is only one of the many factors which determine the ultimate fate of a drug, and arguably far from the predominant one in the United States.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.